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Abstract 
 
Background & Aims: Dietary restriction of fermentable carbohydrates (a low FODMAP diet) 
has been reported to reduce symptoms in some patients with irritable bowel syndrome 
(IBS). We performed a randomized, placebo-controlled study to determine its effects on 
symptoms and the fecal microbiota in patients with IBS. 
 
Methods: We performed a 2x2 factorial trial of 104 patients with IBS (18–65 years old), 
based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly 
assigned (blinded) to groups given counselling to follow a sham diet or diet low in FODMAPs 
for 4 weeks, along with a placebo or probiotic supplement (VSL#3), resulting in 4 groups (27 
receiving sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP 
diet /placebo, and 27 receiving low FODMAP diet /probiotic). The sham diet restricted a 
similar number of staple and non-staple foods as the low FODMAP diet; the diets had similar 
degrees of difficulty to follow. Dietary counselling was given to patients in all groups and 
data on foods eaten and compliance were collected. The incidence and severity of 15 
gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the 
study period; along with stool frequency and consistency. At baseline, global and individual 
symptoms were measured, along with generic and disease-specific health-related quality of 
life, using standard scoring systems. All data were collected again at 4 weeks, and patients 
answered questions about adequate symptom relief. Fecal samples were collected at 
baseline and after 4 weeks and analyzed by quantitative PCR and 16S rRNA sequencing. The 
co-primary endpoints were adequate relief of symptoms and stool Bifidobacterium species 
abundance at 4 weeks. 
 
Results: There was no significant interaction between the interventions in adequate relief of 
symptoms (P=.52) or Bifidobacterium species (P=.68). In the intention-to-treat analysis, a 
higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) 
vs than in the sham diet group (38%), although the difference was not statistically significant 
(P=.051). In the per-protocol analysis, a significantly higher proportion of patients on the 
low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) 
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(P=.043). Total mean IBS- Severity Scoring System score was significantly lower for patients 
on the low FODMAP diet (173±95) than the sham diet (224 ± 89)(P=.001), but not different 
between those given probiotic (207 ± 98) or placebo (192 ± 93)(P=.721) Abundance of 
Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet 
(8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P=.008), but higher in 
patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) 
(P=.019). There was no effect of the low FODMAP diet on microbiota diversity in fecal 
samples.  
 
Conclusions: In a placebo-controlled study of patients with IBS, a low FODMAP diet 
associates with adequate symptom relief and significantly reduced symptom scores 
compared with placebo. It is not clear whether changes resulted from collective FODMAP 
restriction or removal of a single component, such as lactose. Co-administration of the 
probiotic VSL#3 increased numbers of Bifidobacterium species, compared with placebo, and 
might be given to restore these bacteria to patients on a low FODMAP diet. Trial registration 
no: ISRCTN02275221. 
 
KEY WORDS: food sensitivity; fructans; galacto-oligosaccharides; lactose 
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Introduction  
Irritable bowel syndrome (IBS) is a functional bowel disorder with a global prevalence of 
11%
1
 and contributes up to 60% of gastroenterology outpatient appointments.
 2
 Diagnosis 
requires the presence of abdominal pain and disordered bowel habit, and although IBS has 
no impact on mortality it profoundly affects health-related quality of life (HRQOL)
3
 likely due 
to its chronic nature and the co-existence of gastrointestinal (GI) and extra-intestinal 
symptoms. It also results in significant economic healthcare burden. Factors that are 
recognised as important in the aetiology of IBS include visceral hypersensitivity, immune 
dysregulation, the GI microbiota, altered regulation of the gut-brain axis, and psychosocial 
factors.
4
 An incomplete understanding of the pathophysiology of IBS and its phenotypic 
heterogeneity has led to symptom-directed treatment approaches including anti-
spasmodics and anti-diarrheals. However, less than 40% of patients are satisfied with their 
current treatments.
5
  
 
Most patients with IBS believe their symptoms are diet-related. Dietary restriction of 
fermentable carbohydrates (low FODMAP diet) is now widely used in the management of 
IBS. These carbohydrates increase small intestinal water and colonic gas.
6
 Their dietary 
restriction has been investigated in a number of trials with up to 70% of patients reporting 
symptomatic benefit.
6
 Only one placebo-controlled trial of the low FODMAP diet has been 
undertaken in IBS, however this was a feeding study in which all dietary intake was provided 
to participants.
7
 Trials of dietary advice replicate how dietary manipulation is undertaken in 
practice and therefore better reflect effectiveness in the clinical setting. Placebo-controlled 
trials are especially important in IBS where the placebo response is known to be 
considerable.
8
 A placebo-controlled dietary advice trial of the low FODMAP diet has yet to 
be performed, in part due to the difficulty of designing a blinded placebo diet that modifies 
dietary intake without altering intakes of nutrients or fermentable carbohydrates.  
 
The low FODMAP diet has been shown to induce alterations in some genera of the GI 
microbiota, including bifidobacteria
9,10
 and Faecalibacterium prausnitzii.
9
 Reductions in 
bifidobacteria are particularly relevant to IBS symptomatology given their inverse 
association with abdominal pain.
11
 There is also evidence of reduced microbiome diversity 
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in IBS
12
, as well as in other disorders (e.g. inflammatory bowel disease, obesity and 
diabetes).
13,14
 There is reason to suspect that the low FODMAP diet may impact global 
microbial community structure, however the effect has never been compared with 
placebo.
15
 It also remains to be demonstrated whether any potential clinical benefit of the 
low FODMAP diet in IBS is offset by impacts on specific microbiota (e.g. bifidobacteria) or on 
community structure, known to be a key factor influencing gut health and systemic 
physiology.
 
 
Therefore, approaches that prevent the microbiota-modifying effect of the low FODMAP 
diet are required. Probiotics are live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host, and some probiotic species are effective in 
the management of IBS.
16
 However, no trials have investigated whether probiotics can 
modify the effect of the low FODMAP diet on the microbiota.  
 
We designed a placebo-controlled trial to address these important questions. Firstly, we 
aimed to investigate the effect of the low FODMAP diet compared with a placebo (sham) 
diet, and secondly, to investigate whether the low FODMAP diet-induced alterations in the 
microbiota could be prevented through concomitant probiotic therapy compared with 
placebo. 
 
Methods 
Study design and participants 
We performed a 2x2 factorial design, multicentre, randomised, placebo-controlled trial from 
clinics at two hospitals in London, UK. Patients aged 18-65 years of age with diarrhoea-
predominant (IBS-D), mixed subtype (IBS-M) or unsubtyped irritable bowel syndrome (IBS-
U), according to Rome III were recruited. Major medical conditions such as inflammatory 
bowel disease and diabetes were excluded, and coeliac disease was excluded by evaluation 
of endomysial IgA, tissue transglutaminase IgA serology or endoscopic biopsy. Patients with 
IBS-C were excluded due to the potential for exacerbation of symptoms on a low FODMAP 
diet based on the aforementioned impact of FODMAPs on small intestinal water. Only 
patients naïve to the low FODMAP diet were recruited (to improve blinding), which was 
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assessed by interview regarding any previous or current dietary restrictions and a diet 
history without reference to FODMAPs. Exclusion criteria included abdominal pain or 
discomfort for less than 2 days during the screening week and patients already following a 
restrictive exclusion diet for IBS were excluded. Lactose intolerance was not tested for and 
was not an exclusion criterion per se, although those with a pre-determined diagnosis who 
had symptom resolution during a low lactose diet would not be eligible due to symptom 
severity criteria. Patients with IBS already following a low lactose diet were eligible as long 
as they agreed to maintain consistent lactose intake during the study period, irrespective of 
diet randomisation. Other exclusion criteria included bowel preparation for investigative 
procedures, antibiotic therapy, prebiotics or probiotics, and change to IBS medication during 
the previous four weeks. Where this occurred during the trial it was considered a protocol 
violation and the patient was withdrawn and excluded from the per protocol analysis. 
Research ethics committee approval was received from the London Fulham Research Ethics 
Committee (Reference 12/LO/1402) and patients gave informed consent prior to 
participation.  
 
Randomisation and masking 
A computerised random allocation sequence was prepared by a researcher not involved in 
screening or recruitment. Patients were randomised in a 1:1 ratio to both diet (sham vs low 
FODMAP diet) and supplement (placebo vs probiotic) resulting in allocation to one of four 
treatment groups (sham diet/placebo, sham diet/probiotic, low FODMAP diet /placebo, low 
FODMAP diet /probiotic). Randomisation was stratified by gender and diagnosis of IBS-D. 
The diet allocation was concealed in an opaque envelope that was only opened after all 
baseline data had been collected.  
 
Patients were masked to both diet and supplement allocations. The two diets were 
described to patients as both altering carbohydrate intake, but one designed as a placebo 
diet and the other being the true diet under investigation. The researcher who conducted 
the trial visits, a registered dietitian, provided the dietary advice and was not able to be 
masked to diet allocation but was masked to supplement allocation. The placebo and 
probiotic supplements were identical in appearance, taste and presentation. Labelling of 
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supplements was performed by researchers not involved in patient screening or recruitment 
such that boxes of supplement sachets were identifiable only by participant randomisation 
numbers. Allocation to diet and supplement was masked throughout data collection, 
laboratory analysis, data input and data analysis. 
 
Procedures 
The low FODMAP diet involves restricting dietary intake of fructans, galacto-
oligosaccharides (GOS), lactose, fructose in excess of glucose, and polyols, and is described 
elsewhere.
17
 Blinding dietary advice trials is notoriously challenging and therefore the sham 
diet was designed bespoke for this trial to fulfil the following criteria:
 18
 [1] to be an 
exclusion diet that restricts a similar number of staple and non-staple foods and requires 
similar difficulty of dietary change to the low FODMAP diet; [2] to require similar intensity 
and duration of dietary counselling as the low FODMAP diet; and [3] not to impact on 
intakes of nutrients, fibre and FODMAPs. For example, suitable carbohydrates on the sham 
diet included fruits such as apple, banana and pear, whereas orange, raspberry, and 
strawberry were not allowed, and allowed grains included wheat but not rice. 
 
The sham diet was field tested to examine fulfilment of these criteria in a pilot study and an 
interim analysis of fibre and FODMAP intake was performed in the current trial following 
completion of 20 patients. Dietary counselling for the sham diet and low FODMAP diet 
lasted for similar duration (approximately 10 minutes) and detailed written food lists were 
provided. Dietary compliance to both sham diet and low FODMAP diet was self-reported 
weekly during telephone calls (‘in the last week I have followed the diet…’) using compliance 
categories adapted from previous work: 
19
 never/rarely (<25% of the time), sometimes (25-
50% of the time), frequently (51-75% of the time) or always (76-100% of the time). Patients 
were considered compliant if they reported following the diet frequently or always (i.e. 
>50% of the time) on at least two of the four weekly assessments. 
 
The probiotic was a multi-strain preparation containing Streptococcus thermophilus DSM 
24731, Bifidobacterium breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737, 
Lactobacillus acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. 
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delbrueckii subsp. bulgaricus DSM 24734 (VSL#3, CD Investments VSL Pharmaceuticals Inc, 
Rome, Italy) and was provided in sachets in freeze dried form with maltose and silicon 
dioxide as inactive excipients. The placebo sachets were prepared by the same 
manufacturer as the probiotic product. The placebo sachets contained the same inactive 
excipients but no bacteria. Participants received two sachets per day (11.95 log10 bacteria in 
the intervention group) to be taken in the morning with cold food or fluid. Patients were 
considered compliant to the supplement if 80% of sachets were taken based on return of all 
unused sachets. A greater threshold for compliance was used for the probiotic/placebo, in 
line with those used in other probiotics trials and because compliance once per day is easier 
than extensive dietary modification at every meal, snack and drink. 
 
Assessments 
The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were 
measured daily for seven days prior to baseline using the Gastrointestinal Symptom Rating 
Scale (GSRS),
20
 and stool frequency and consistency was recorded using the Bristol Stool 
Form Scale. A 7-day food diary was used to measure dietary intake and FODMAP intake was 
quantified using dietary analysis software containing the most comprehensively analysed 
FODMAP food composition database available.
21-23
 At the baseline visit, global and 
individual symptoms were also measured using the IBS Symptom Scoring System (IBS-SSS).
24
 
Generic and disease-specific HRQOL were measured using the SF-36
25
 and IBS-QOL
26
, 
respectively. Then, after all data had been collected, patients were randomised to dietary 
advice (sham, low FODMAP diet) and supplement (placebo, probiotic). Patients were 
telephoned weekly for assessment of dietary compliance, to address dietary questions and 
to ensure IBS medication remained stable. All outcomes were then repeated at four weeks 
(follow-up) as well as ‘adequate symptom relief’ (did you have adequate relief of your 
symptoms over the past seven days).
 27
  
 
A whole fresh stool sample was collected within one hour of passage and stored 
immediately on ice at baseline and follow-up. It was homogenized in a stomacher for four 
minutes and multiple aliquots were taken and stored at -80°C until analysis. Quantitative 
polymerase chain reaction (qPCR) was performed to quantify abundance of Bifidobacterium 
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species. 16S rRNA sequencing was performed to evaluate α-diversity (number of operational 
taxonomic units [OTU] i.e. number of species, or richness) and β-diversity (differences in 
species composition between baseline and follow-up) and to confirm the abundance of 
Bifidobacterium species from qPCR analysis (supplementary Information). 
 
Outcomes 
As the outcomes of interest were the impact of diet and supplement on symptoms and 
microbiota, the co-primary outcomes were IBS symptoms (‘adequate symptom relief’) and 
stool Bifidobacterium species concentration at follow-up, measured using qPCR. Pre-
specified secondary outcomes were individual GI symptoms (IBS-SSS and GSRS), stool 
output, HRQOL, microbiota diversity and nutrient intake. Adverse events were recorded at 
weekly telephone calls and at the follow-up visit.  
 
Statistical analysis  
The sample size calculation was based on the co-primary endpoints assuming no interaction 
between the two interventions. For the first co-primary outcome (symptoms), the estimated 
response to low FODMAP diet advice was based upon ‘adequate symptom relief’ from the 
only randomised controlled trial (RCT) available at the time (68%)
10
 and the estimated 
response to sham advice was based on the response rate of controls in a meta-analysis of 
IBS trials and two previous trials of the low FODMAP diet (36%).
10,28,29
 The estimated 
response to the probiotic and placebo was based upon the combined global response data 
from previous studies of the probiotic supplement.
30,31
 Based on logistic regression and 
assuming a power of 80% and a 2-sided significance level of 5%, the main effects of diet 
(sham vs low FODMAP diet) could be estimated with 88 patients. Based on previous 
research from our centre
10
,
 
attrition of at least 12% was anticipated, leading to an overall 
sample size of at least 100 such that the per protocol analysis would be adequately 
powered. For the second co-primary outcome (Bifidobacterium), the expected abundance of 
stool Bifidobacterium species in response to the low FODMAP diet was taken from the only 
RCT at that time
10
 and the expected abundance in response to probiotic was taken from a 
VSL#3 RCT. 
32
 The sham and placebo groups were expected to have no impact on abundance 
of Bifidobacterium species and therefore values from control groups were used. Based on 
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linear regression, assumed power of 80% and overall 2-sided significance of 5%, the main 
effects for the Bifidobacterium outcome could be estimated with 28 patients, which ensured 
the trial was powered for both clinical and microbiological outcomes. 
 
The primary analysis was by intention-to-treat. A subsequent per protocol analysis was 
performed for the symptom primary outcome using data from completed patients who did 
not violate the protocol and were compliant with the interventions. The qPCR and 16S rRNA 
sequencing analysis is presented for the per protocol population. Data are presented as 
summary data e.g. mean (SD) for continuous variables or number (%) for categorical data 
with estimates and 95% confidence intervals (CI). Differences were considered significant 
where p≤0.05. 
 
Linear regression and ANOVA was performed to evaluate the effect of diet and supplement 
on continuous variables (microbiota according to qPCR, IBS-SSS, GSRS symptom severity, 
stool output, HRQOL). The Chi-squared test and logistic regression was performed to 
evaluate the effect on categorical variables (‘adequate symptom relief’, proportion meeting 
minimal clinically important difference [MCID] for IBS-SSS, IBS-QOL). Adjusted regression 
models were performed to account for differences between groups at baseline and 
bootstrapping was computed due to non-normal data. Interaction terms were added into 
regression models to check for interactions between the two independent variables (diet, 
supplement). The Kruskal-Wallis test and Wilcoxon rank sum test were used to evaluate 
differences in microbiota diversity and abundance according to 16S rRNA sequencing 
between groups and over time within groups, respectively. A correction was applied for 
multiple comparisons where required. Intake of FODMAPs, energy and nutrients were 
compared between diet groups using analysis of covariance (ANCOVA), adjusting for 
baseline. Statistical analysis was performed using IBM SPSS Statistics Version 22.0.  
 
All authors had access to the trial data and reviewed and approved the final manuscript.  
 
Results 
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Patients were recruited between 28 January 2013 and 21 November 2014. A total of 162 
patients were screened of whom 58 were ineligible. Therefore, 104 patients were 
randomised to the sham (n=53) or low FODMAP diet (n=51) and placebo (n=51) or probiotic 
(n=53) as follows: sham/placebo (n=27), sham/probiotic (n=26), low FODMAP diet/placebo 
(n=24) and low FODMAP diet /probiotic (n=27) (Figure 1). Nine patients were withdrawn 
from the trial (six commenced antibiotics [two sham, four low FODMAP diet], one violated 
the protocol by following an alternative diet [sham], one was lost to follow-up [sham], one 
withdrew for personal reasons [sham]), five were non-compliant with placebo [two sham, 
three low FODMAP diet] and three were non-compliant with probiotic [two sham, one low 
FODMAP diet]). All 104 randomised patients were included in the intention-to-treat analysis 
and 87 were included in the per protocol analysis. Baseline characteristics of patients were 
similar for both diet and supplement interventions (Table 1). Medications used included 
antidiarrheals (loperamide), analgesics (acetaminophen, non-steroidal anti-inflammatories) 
and antispasmodics (butylscopolamine). 
 
All patients reported following the diet >50% of the time on at least two of the four weeks 
and were defined as compliant to the dietary interventions. Of the 95 patients who 
completed the study, 88 (93%) patients reported always following the diet (76-100% of the 
time) over the four weeks, 7 (7%) reported frequently following the diet (51-75% of the 
time) and no patients reported following the diet sometimes (25-50% of the time) or never. 
At follow-up, dietary advice resulted in lower total FODMAP intake in the low FODMAP diet 
group (9·9 g/d) compared with the sham diet group (17.4 g/d, p<0.001), with significantly 
lower intakes of a number of individual FODMAPs (p<0.05). There was no difference 
between low FODMAP diet and sham diet for intakes of total energy, macronutrients or 
fibre (non-starch polysaccharide) (Table 2). Of the 95 that completed the study, 87 (92%) 
patients were defined as compliant to the probiotic/placebo, defined as consuming at least 
80% of sachets (based upon returned sachets; 88 (93%) patients consumed 76-100% of 
sachets, 6 (6%) consumed 51-75% of sachets, 1 (1%) consumed 26-50%, and 1 (1%) 
consumed 0-25% of sachets.  
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There was no interaction between the interventions for either co-primary outcome 
(interaction term for adequate relief OR 0.60 (95% CI 0.12 to 2.97, p=0.52) and 
Bifidobacterium species mean difference -0.10 (95% CI -0.59 to 0.38, p=0.68). Therefore the 
results are presented separately for diet (sham vs low FODMAP diet) and supplement 
(placebo vs probiotic) interventions. 
 
Clinical endpoints 
At follow-up, in the intention-to-treat analysis there was a higher proportion of patients 
reporting ‘adequate symptom relief’ for the low FODMAP diet (29/51, 57%) compared with 
sham diet (20/53, 38%), although the difference was not statistically significant (χ
2
=3.816, 
p=0.051), with an odds of symptom relief of 2·18 (95% CI 0.99 to 4.77, p=0.052). However, 
in the per protocol analysis more patients reported ‘adequate symptom relief’ for the low 
FODMAP diet (26/43, 61%) than for sham diet (17/44, 39%) (χ
2
=4.146, p=0.042), with an 
odds of symptom relief of 2.43 (95% CI 1.03 to 5.75, p=0.043).  
 
At follow-up, the proportion of patients reporting ‘adequate symptom relief’ for the 
probiotic (30/53, 57%) compared with placebo (19/51, 37%) achieved statistical significance 
(χ
2
=3.905, p=0.048), with an odds of symptom relief of 2·20 (95% CI 1.00 to 4.82, p=0.050). 
However, in the per protocol analysis the proportion of patients reporting ‘adequate 
symptom relief’ for probiotic (27/47, 57%) compared with placebo (16/40, 40%) was not 
significant (χ
2
=2.631, p=0.105), and nor were the odds of symptom relief (OR 2.03, 95% CI 
0.86 to 4.77, p=0.107).   
 
In the intention-to-treat population at follow-up, the total IBS-SSS score was significantly 
lower for the low FODMAP diet (173 ± 95) compared with sham diet (224 ± 89, p=0.001), 
and there were lower subscores for days of pain (p=0.001), distension severity (p=0.002), 
satisfaction with bowels (p=0.002) and the impact of IBS symptoms on life (p=0.022, Table 
3). A higher proportion of patients achieved the MCID (reduction in total IBS-SSS score of 
≥50) during the low FODMAP diet (37/51, 73%) compared with the sham diet (n=22/53, 
42%) (OR 3.72, 95% CI 1.64 to 8·48, p=0.0017). There were also lower severity scores for a 
number of symptoms including abdominal pain (p=0.010) and overall symptoms (p=0.020) 
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according to the GSRS, and a lower stool consistency score (p=0.008) in patients following 
the low FODMAP diet compared with the sham diet. There was no difference in the 
proportion of patients achieving the MCID for probiotic (32/53, 60%) versus placebo (27/51, 
53%) (OR 1.49 95% CI 0.63 to 3.52, p=0.363), or for GSRS or stool output outcomes, except 
for lower severity for flatulence (p=0.033, Table 3).  
 
Although there were no differences between groups in total score for SF-36 and IBS-QOL 
(Table 4), there were higher scores for role limitations due to physical health (p=0.033) and 
energy/fatigue (p=0.016) for SF-36 and higher scores for body image (p=0.001), social 
reaction (p=0.026) and relationships (p=0.041) of IBS-QOL in patients on the low FODMAP 
diet compared with sham diet, indicating better quality of life in these domains. There was 
no effect of probiotic on HRQOL compared with placebo (Table 4). 
 
Microbiota endpoints 
Regarding the microbiota co-primary endpoint using the qPCR analysis, at follow-up there 
was a lower absolute Bifidobacterium species abundance following the low FODMAP diet 
(8.8 16S rRNA genes/g, SD 0·6) compared with sham diet (9.2 rRNA genes/g, SD 0·9) (mean 
difference -0.39 rRNA genes/g, 95% CI -0.64 to -0.13, p=0.008). At follow-up there was 
greater absolute abundance of Bifidobacterium species for probiotic (9.1 rRNA genes/g, SD 
0·6) compared with placebo (8.8 rRNA genes/g, SD 1.0) (mean difference +0.34 rRNA 
genes/g, 95% CI 0.05 to 0.61, p= 0.019).  
 
16S rRNA sequencing confirmed the low FODMAP diet led to a significant reduction in 
relative abundance of Bifidobacterium species between baseline and follow-up (1.70% vs 
0.79%) that did not occur in  sham group (1.57% vs 1.93%), representing a mean change in 
the low FODMAP diet of -0.91% compared with sham 0.36% (95% CI for differences in 
change 0.45% to 2.09%, p=0.0027, Figure 2A). In contrast, there were no differences in the 
change in relative abundance of Bifidobacterium species between baseline and follow-up 
between the probiotic group (1.60% vs 1.50%) compared with the placebo group (1.68% vs 
1.18%), with a mean change in the low FODMAP diet of -0.99% vs sham -0.50% (95% CI for 
differences in change -0.46% to 1.20%, p=0.3549, Figure 2A). However, 16S rRNA 
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sequencing demonstrated a significant increase in relative abundance of Streptococcus 
species in the probiotic group (0.45% vs 1.90%) compared with placebo (0.38% vs 0.55%), 
representing a mean change in the probiotic group of 1.45% compared with placebo 0.17% 
(95% CI for differences in change 0.63% to 1.90%, p=0.00017, Figure 2B). There was no 
difference in relative abundance of Streptococcus species for the low FODMAP diet 
compared with sham diet (p=0.1141, Figure 2B). There were also no differences in change in 
relative abundance of Lactobacillus species between baseline and follow-up between the 
low FODMAP diet and sham diet (p=0.5782) or between the probiotic and placebo group (p= 
0.9521, Figure 2C).   
 
There were significant differences in absolute abundance of Bifidobacterium species 
measured using qPCR between the four randomised groups at follow-up, i.e. sham 
diet/placebo (8.9 rRNA genes/g, SD 1.2), low FODMAP diet/placebo (8.6 rRNA genes/g, SD 
0.5), sham diet/probiotic (9.2 rRNA genes/g, SD 0.5), low FODMAP diet/probiotic (8.9 rRNA 
genes/g, SD 0.6) (ANOVA p=0.037),  with a significant difference specifically between low 
FODMAP diet/placebo versus sham diet/probiotic (mean difference -0.67, 95% CI -1.25 to -
0.08, p=0.020; Games-Howell post hoc correction). 
 
16S rRNA sequencing analysis revealed no significant differences in global microbiota α-
diversity (Chao index) following a low FODMAP diet (mean change 824.0) compared with 
sham diet (286.6) (95% CI for differences in change -840.2 to 1915.1, p=0.401) or between 
probiotic (mean change 298.1) and placebo (867.7) (95% CI for differences in change -815.5 
to 1954.7, p=0.212). Neither were there differences in the change in α-diversity between 
the four randomised groups (p=0.473).  
 
There was no difference in β-diversity (Bray Curtis dissimilarity index) for the low FODMAP 
diet compared with sham diet (mean difference -0.010, 95% CI -0.044 to 0.024, p=0.575) or 
for probiotic compared with placebo (mean difference -0.004, 95% CI -0.039 to 0.032, 
p=0.833). 
 
Adverse events 
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Overall, the number of adverse events reported was small. Six patients reported worsened 
GI symptoms (four sham, two low FODMAP diet; four placebo, two probiotic). Other 
adverse events not thought to be related to the diet or supplement were reported in 40% of 
patients (e.g. headache, cold, toothache) and this was not different between diet (p=0.516) 
or supplement groups (p=0.388). No serious adverse events were reported.  
 
Discussion 
This RCT demonstrates that low FODMAP dietary advice leads to adequate relief of GI 
symptoms in 57% of patients compared with 38% of patients receiving sham dietary advice 
(and 61% and 39% in the per protocol analysis). Although this finding did not reach 
statistical significance, the totality of the clinical outcomes reported here point toward the 
clinical effectiveness of the low FODMAP diet over and above placebo, the first to do so 
using dietary advice, making it directly relevant to clinical practice. Low FODMAP dietary 
advice was shown to restrict FODMAP intake whilst not altering energy and macronutrient 
intake compared with sham diet advice, indicating that the observed effects are likely the 
result of FODMAP restriction rather than changes in nutrient intake. Furthermore, this RCT 
evaluated whether the low FODMAP diet-induced decline in bifidobacteria
9,10
 can be 
modified by probiotic supplementation.  
 
Despite the low FODMAP diet resulting in significantly lower composite and individual 
symptom scores according to a range of validated instruments, the proportion reporting the 
co-primary endpoint of ‘adequate symptom relief’ during the low FODMAP diet compared 
with sham diet was only of borderline statistical significance. There are several issues that 
explain this discrepancy. Firstly, the proportion of patients achieving ‘adequate symptom 
relief’ after the low FODMAP diet (57%) was lower than reported in a previous low FODMAP 
dietary advice trial (68%)
10
; dietary allocation in the previous study was unblinded and 
therefore the response may have been artificially enhanced. Secondly, in the current RCT, 
the blinded low FODMAP dietary advice was delivered without explanation of how the diet 
affects GI physiology, as is done in routine clinical practice and which may be important for 
enhancing patient ‘buy in’. This also led to the patient education process being of shorter 
duration than that which would normally be applied in clinical practice. Thirdly, analysing 
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only those who completed the study and complied with the intervention resulted in 
statistically significant differences between groups in favour of the low FODMAP diet. 
 
Although the ‘adequate symptom relief’ endpoint is currently considered an important 
outcome measure in IBS trials
4
 and has been used as the primary endpoint in drug trials (e.g. 
alosetron, tegaserod) it has several limitations. First, a binary response requires synthesis of 
multiple symptoms into a single response and does not allow detail regarding individual 
symptoms, which is better captured by a multi-item instrument (e.g. IBS-SSS). Second, it is 
not possible to quantify the magnitude of symptom improvement. Finally, it requires 
subjective assessment of whether symptoms are adequately controlled, which is likely to 
have high inter-individual variation. Conversely, the presence of a minimal clinically 
important difference for the IBS-SSS allows for meaningful interpretation of the score.
24
  
 
Previous non-placebo controlled low FODMAP dietary advice trials have reported similar 
changes in IBS-SSS score over time (-78 to -133 points) to that reported here (mean -117 
points).
33,34
 Moreover, the impact of the low FODMAP diet on abdominal pain, bloating, 
flatulence, urgency, and stool consistency are supportive of results from previous RCTs
7,10
, 
and are likely explained by the effect of fermentable carbohydrates on small intestinal water 
and colonic gas production. This trial also reported a significant benefit of the low FODMAP 
diet on aspects of HRQOL in a blinded RCT, an endpoint which is particularly pertinent in IBS. 
Whether the positive impact on some domains of HRQOL translates into reduced healthcare 
utilisation or has wider economic implications requires evaluation. 
 
‘Adequate symptom relief’ was reported in more patients receiving probiotic than the 
placebo. Although this was statistically significant this may represent a type I error; the trial 
was not powered to detect differences in this outcome for the probiotic and yet the effect 
size was much higher (57%) compared with previous studies of VSL#3 (33%-46%)
30,31
, and no 
differences were found in the per protocol analysis. Furthermore, the ‘adequate symptom 
relief’ outcome distinctly deviates from other clinical endpoints in this trial.  
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As hypothesised, the low FODMAP diet led to a reduction in stool Bifidobacterium species 
according to qPCR and 16S rRNA sequencing. These findings are likely the result of 
restriction of prebiotic carbohydrates, essentially leading to the opposite effect to that 
which occurs during prebiotic supplementation (an ‘anti-prebiotic’ effect). Bifidobacteria 
have established immunomodulatory effects and have been inversely associated with 
clinical symptoms in IBS.
11
 The impact of the reduction of Bifidobacterium species by the low 
FODMAP diet on clinical symptoms in IBS, or on colonic function is unknown. However, the 
probiotic, which contained bifidobacteria strains, resulted in a greater abundance of 
Bifodobacterium species according to qPCR analysis. This finding was not replicated in the 
sequencing analysis, although this discrepancy is not uncommon and can be attributed to 
the fact that qPCR is a quantitative method using specific primer sets to enumerate the 
population of interest whereas 16S rRNA sequencing targets the whole bacterial 
community, sometimes failing to provide extensive coverage for specific genera. Given the 
lack of interaction between diet and probiotic interventions in this study, the effects of each 
can be considered additive. We have therefore shown that the low FODMAP diet-induced 
reduction in Bifidobacterium can be modified with the addition of a specific bifidobacteria-
containing probiotic.   
 
Reduced microbiome species richness is evident in IBS, as well as in inflammatory bowel 
disease, obesity and diabetes.
13,14
 Two previous studies report no within-group change in 
microbiota diversity in response to the low FODMAP diet,
15,35
 and another has 
demonstrated increased richness in Clostridial Cluster XIV compared with habitual diet.
9
 
However, the effect of the low FODMAP diet on microbiota diversity compared with a 
placebo diet has not been examined. Here we have shown that the low FODMAP diet does 
not affect α-diversity or β-diversity compared with a sham control diet. Given the reduction 
of carbohydrate available for colonic fermentation during the low FODMAP diet, the 
absence of an impact on diversity is reassuring, particularly in view of its negative 
associations with gastrointestinal and extra-intestinal disease.  
 
This RCT evaluated the therapeutic benefit of low FODMAP dietary advice, as utilised in 
clinical practice, above the effect of placebo, which is known to have a powerful effect in 
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IBS.
8
 In dietary intervention trials, the problem of designing a control group is often resolved 
through feeding studies that deviate considerably from clinical practice. Therefore an 
important strength of the current study is the implementation of a placebo sham diet that 
required equivalent dietary counselling, disruption to daily life, and which changed dietary 
intake but not FODMAP intake.  
 
Limitations of this RCT include the difficulty of maintaining blinding. Blinding is challenging 
in dietary intervention trials compared with nutrient or drug trials. However, the best 
attempts were made to blind patients to their allocated diet through a range of approaches: 
the sham diet also focused on modifying intake of carbohydrate-rich foods, required 
modification of a similar number of foods and specialist foods compared with the low 
FODMAP diet, and the burden of teaching and following the sham diet was equivalent to the 
low FODMAP diet.  Second, as the study was performed in secondary care and excluded 
patients with constipation-predominant IBS, it is not possible to say if the results are 
applicable beyond this setting. Third, although there was a measurable reduction in total 
FODMAP intake, it is unknown whether symptom response was due to collective FODMAP 
restriction or the removal of one (e.g. lactose, fructans) or several individual FODMAPs.  
Fourth, there is the problem of collinearity, which is unavoidable in dietary exclusion studies 
(i.e. changing one component of the diet leads to compensatory changes in other 
components). Although macronutrient and fibre intake was maintained in this study, there 
may have been changes in unmeasured dietary substrates (e.g. polyphenols, gluten) that 
could contribute to the observed findings. This limitation is also applicable to the sham 
group; there may have been alteration in unmeasured dietary components that impacted 
the findings. However, we carefully measured intake of numerous dietary constituents with 
an established potential to impact IBS symptoms (e.g. fiber, fat) and these did not change, 
suggesting it fulfilled its purpose as a sham diet. Fifth, changing dietary intake may impact 
on other physiological parameters (e.g. transit time) that might independently affect 
microbiota composition. Finally, this study raises questions regarding the use of a 
dichotomous endpoint as a primary outcome measure given the disparity between this 
outcome and the various non-dichotomous endpoints used (e.g. IBS-SSS, GSRS). Trials in IBS-
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C have also reported clinically important changes in individual symptoms in patients that did 
not meet a dichotomous endpoint.
36
  
 
Further research should prospectively evaluate longer term durability of the low FODMAP 
diet, which has been associated with symptom benefit in retrospective studies.
19,38
  It should 
also address the low FODMAP diet-induced microbiota disruption to determine whether the 
microbiota changes persist over time, and whether co-administration of probiotic should be 
considered in the long term. Cost-benefit analysis of both interventions will confirm their 
utility for long term use.  Furthermore, whether the mucosal microbiota compartment is 
affected, whether changes in microbiome function occur (dependent or independent of the 
compositional shift) and whether this leads to short-term or long-term consequences 
require evaluation. Furthermore, the identification of biomarkers that predict response to 
the low FODMAP diet would be extremely valuable. IBS is a heterogeneous syndrome with 
inter-individual differences in the contribution of physiological, cognitive and behavioral 
components to the manifestation of symptoms.  It is currently unclear to what extent each 
of these will respond to dietary and probiotic intervention. 
 
In conclusion, we have demonstrated that low FODMAP dietary advice leads to 
improvement in overall and specific GI symptoms in IBS. In fact, 73% of patients reported a 
global clinical response based on the IBS-SSS, and 57% report response based on the 
dichotomous primary outcome, although the limitations of the latter endpoint are 
acknowledged. At a conservative estimate, this corresponds to a 2-3 greater odds of 
response to low FODMAP dietary advice compared with placebo dietary advice, which is 
equivalent to several pharmaceutical treatments (e.g. antispasmodics, antidepressants).
37
 
We also present findings related to the impact of the low FODMAP diet on the microbiota, 
and the first evidence that the effect of the low FODMAP diet on bifidobacteria can be 
modified by adjunctive probiotic therapy.  
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TABLE AND FIGURE LEGENDS 
Table 1: Demographic data for the intention-to-treat population 
Data are mean (SD) or n (%). BMI= body mass index 
 
 
Table 2:  Dietary intake at follow-up in patients receiving sham dietary advice and low 
FODMAP dietary advice 
Data are mean (SD) at follow up for total and individual FODMAPs (g/d), energy (kcal/d) and 
nutrient intake (g/d). *Total FODMAPs are calculated as the sum of individual carbohydrates 
including excess fructose (not total fructose). NSP=non-starch polysaccharides.  Data were 
log transformed for analysis. 
 
Table 3: Symptom and stool output outcomes at follow-up in patients receiving sham 
dietary advice, low FODMAP dietary advice, placebo and probiotic  
Data are mean (SD) at follow up. *IBS Severity Scoring System (IBS-SSS) instrument scores 
symptom severity on five visual analogue scale items, where worst severity is 500 points. 
†Gastrointesbnal Symptom Rabng Scale (GSRS) instrument, where severity was rated daily 
over seven days on a scale of 0 (absent), 1 (mild), 2 (moderate), 3 (severe). ‡Mean 
consistency based on Bristol Stool Form Scale type over the 7-day period. **Mean number 
of stools over the 7-day period. †† Proportion of stools that were Bristol Stool Form types 3-
5 over the 7-day period.  
 
 
Table 4: Health-related quality of life outcomes at follow-up in patients sham dietary 
advice, low FODMAP dietary advice, placebo and probiotic 
Data are mean (SD) at follow up. 
 
 
Figure 1: CONSORT flow diagram 
 
 
Figure 2: Changes in relative abundance of selected bacterial genera according to 16S 
rRNA sequencing.  
(A) Change in relative abundance of Bifidobacteria for low FODMAP diet (LFD) vs sham diet 
(p=0·0027) and probiotic vs placebo (p=0·3549). (B) Change in relative abundance of 
Streptococcus species for low FODMAP diet vs sham diet (p=0·1141) and probiotic vs 
placebo (p=0·00017). (C) Change in relative abundance of Lactobacillus species for low 
FODMAP diet vs sham diet (p=0·5782) and probiotic vs placebo (p=0·9521) (Wilcoxon rank-
sum test, FDR correction). The central line indicates the median, the box indicates the 25th 
and 75th percentiles and the whiskers indicate 1.5x interquartile range. LFD, low FODMAP 
diet. 
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Tables 
 
Table 1:  
 
 
Sham diet and  
placebo   
(n=27) 
Sham diet and  
probiotic  
(n=26) 
Low FODMAP 
diet and placebo 
(n=24) 
low FODMAP diet 
and probiotic 
(n=27) 
Age (years)  33 (12) 35 (11) 36 (11) 38 (13) 
Female  18 (67) 17 (65) 17 (71) 18 (67) 
Symptom duration (months)  59 (58) 70 (95) 63 (81) 104 (131) 
IBS subtype      
    IBS-D  18 (67) 16 (61) 16 (67) 19 (70) 
    IBS-M  5 (18) 7 (27) 5 (21) 7 (26) 
    IBS-U  4 (15) 3 (12) 3 (13) 1(4) 
Current medications     
    Antidiarrheal  1 (4) 1 (4) 1 (4) 2 (7) 
    Analgesic  0 (0) 0 (0) 3 (13) 1 (4) 
    Antispasmodic  3 (11) 3 (12) 5 (21) 0 (0) 
Ethnicity (white)  22 (82) 23 (89) 19 (79) 22 (82) 
Smoker  1 (4) 2 (8) 0 (0) 5 (19) 
Vegetarian  0 (0) 0 (0) 1 (4) 1 (4) 
Weight (kg)  69 (13) 75 (22) 72 (17) 69 (13) 
BMI (kg/m
2
)  24 (4) 25 (6) 25 (5) 24 (4) 
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Table 2:   
 
Sham diet 
n=53 
Low FODMAP diet 
n=51 
p 
Energy  1891 (599) 1861 (465) 0.517 
Protein  75 (21) 78 (22) 0.100 
Fat  80 (28) 78 (25) 0.787 
Carbohydrate 
 
206 (62) 198 (58) 0.678 
 Starch  115 (39) 110 (39) 0.916 
 Sugars  84 (33) 75 (30) 0.457 
 Non-starch polysaccharide  13.3 (5.1) 12.8 (4.8) 0.578 
Total FODMAPs * 17.4 (10.5) 9.9 (6.4) <0.001 
     Fructans  5.0 (2.9) 2.5 (1.9) <0.001 
     GOS  0.9 (0.5) 0.8 (0.6) 0.080 
     Lactose  8.9 (9.1) 4.3 (4.3) <0.001 
     Total fructose  15.5 (8.7) 12.7 (5.9) 0.112 
     Excess fructose  1.4 (1.4)  1.9 (2.8) 0.821 
     Sorbitol 1.0 (1.0) 0.3 (0.5) <0.001 
     Mannitol  0.3 (0.3) 0.1 (0.2) 0.041 
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Table 3: 
 
 
 
 
 
 
 
 
 
 Diet Supplement 
 Sham diet 
(n=53) 
Low 
FODMAP diet 
(n=51) 
p Placebo 
(n=51) 
Probiotic 
(n=53) 
p 
IBS-SSS*       
Total score 224 (89) 173 (95) 0.001 207 (98) 192 (93) 0.721 
    Pain severity 40 (23) 33 (24) 0.062 38 (24) 35 (24) 0.892 
    Days of pain  44 (29) 30 (27) 0.001 39 (28) 35 (30) 0.690 
    Distension severity 40 (24) 29 (25) 0.002 34 (24) 35 (26) 0.766 
    Satisfaction with bowels 
wihbbowels 
53 (17) 42 (23) 0.002 49 (22) 46 (20) 0.459 
    Affecting life 47 (21) 40 (20) 0.022 46 (21) 41 (20) 0.322 
Change in IBS-SSS -44 (72) -117 (86) 0.001 -78 (96) -82 (78) 0.750 
†Gastrointes>nal Symptom Ra>ng Scale Severity Scores 
Abdominal pain 1.1 (0.6) 0.9 (0.7) 0.010 1.0 (0.7) 0.9 (0.6) 0.753 
Heartburn 0.2 (0.3) 0.2 (0.5) 0.872 0.2 (0.3) 0.2 (0.5) 0.128 
Acid reflux 0.2 (0.5) 0.2 (0.4) 0.515 0.2 (0.3) 0.2 (0.4) 0.276 
Nausea 0.3 (0.5) 0.3 (0.4) 0.535 0.3 (0.6) 0.2 (0.3) 0.191 
Borborygmi 1.0 (0.7) 0.7 (0.6) 0.003 0.9 (0.7) 0.8 (0.7) 0.913 
Bloating 1.1 (0.7) 0.8 (0.7) 0.001 1.0 (0.7) 1.0 (0.7) 0.780 
Belching 0.6 (0.7) 0.5 (0.6) 0.031 0.6 (0.7) 0.5 (0.6) 0.084 
Flatulence 1.3 (0.7) 0.9 (0.6) 0.001 1.2 (0.7) 1.0 (0.6) 0.033 
Constipation 0.3 (0.4) 0.2 (0.4) 0.559 0.2 (0.4) 0.3 (0.4) 0.452 
Diarrhoea 0.3 (0.5) 0.2 (0.5) 0.257 0.3 (0.5) 0.2 (0.4) 0.505 
Loose stool 0.7 (0.7) 0.5 (0.6) 0.080 0.7 (0.7) 0.5 (0.6) 0.542 
Hard stool 0.2 (0.2) 0.2 (0.3) 0.166 0.2 (0.2) 0.2 (0.3) 0.203 
Urgency 0.7 (0.6) 0.6 (0.7) 0.001 0.7 (0.7) 0.6 (0.6) 0.610 
Incomplete evacuation 0.7 (0.7) 0.5 (0.6) 0.039 0.7 (0.7) 0.6 (0.6) 0.674 
Tiredness 1.3 (0.7) 1.0 (0.8) 0.067 1.2 (0.8) 1.0 (0.8) 0.393 
Overall symptoms 1.2 (0.6) 1.0 (0.6) 0.020 1.2 (0.6) 1.0 (0.6) 0.066 
Stool output 
Stool consistency‡ 4.3 (1.1) 3.9 (1.0) 0.008 4.2 (1.0) 4.0 (1.1) 0.544 
Normal consistency    
(propor>on) †† 
61 (30) 67 (26) 0.200 64 (30) 64 (26) 0.689 
Stool frequency** 
 
12.9 (7.4) 14.0 (8.5) 0.843 13.8 (8.3) 13.1 (7.6) 0.136 
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Table 4: 
 
 
 
 
 Diet Supplement 
 
Sham diet 
(n=53) 
Low 
FODMAP diet 
(n=51) 
p 
Placebo 
(n=51) 
Probiotic 
(n=53) 
p 
SF-36       
Physical functioning 87.3 (22.3) 86.3 (21.3) 0.357 88.9 (19.2) 84.7 (23.8) 0.278 
Role limitations due to physical health 55.2 (39.6) 70.6 (39.3) 0.033 62.8 (39.8) 62.7 (40.6) 0.330 
Role limitations due to emotional problems 65.4 (37.5) 64.1 (43.1) 0.598 71.2 (38.3) 58.5 (41.3) 0.330 
Energy/fatigue 42.6 (19.9) 52.1 (23.3) 0.016 43.9 (19.7) 50.4 (23.8) 0.427 
Emotional wellbeing 63.3 (17.3) 68.7 (17.8) 0.082 66.0 (17.8) 65.8  (17.7) 0.991 
Social functioning 77.8 (20.7) 73.3 (27.3) 0.398 76.0 (25.0) 75.2 (23.6) 0.731 
Pain 65.1 (20.4) 63.5 (27.0) 0.349 61.0 (23.7) 67.5 (23.6) 0.460 
General Health 56.2 (19.7) 57.5 (22.4) 0.141 55.8 (20.7) 57.8 (21.4) 0.235 
IBS-QOL       
Overall 70.6 (18.1) 72.4 (19.7) 0.057 68.6 (20.7) 74.3 (16.6) 0.849 
Dysphoria 72.2 (20.5) 71.9 (24.7) 0.640 69.6 (24.7) 74.4 (20.3) 0.937 
Interference with activity 71.2 (20.6) 72.9 (24.2) 0.120 68.9 (23.3) 75.0 (21.1) 0.640 
Body Image 64.2 (22.7) 73.2 (22.7) 0.001 64.8 (24.2) 72.2 (21.5) 0.847 
Healthy worry 71.1 (20.8) 73.0 (20.0) 0.383 69.6 (23.3) 74.4 (17.0) 0.336 
Food avoidance 57.9 (29.2) 51.1 (26.7) 0.823 53.6 (28.8) 55.5 (27.5) 0.683 
Social reaction 71.7 (22.2) 77.5 (22.4) 0.026 71.2 (23.3) 77.7 (21.1) 0.769 
Sexual 76.2 (28.6) 79.7 (24.7) 0.163 73.3 (29.3) 82.3 (23.4) 0.150 
Relationships 80.5 (19.9) 81.2 (18.8) 0.041 77.5 (20.1) 84.1 (18.1) 0.451 
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162 assessed for eligibility  
58 ineligible 
     2 taking probiotic 
     1 taking lactulose 
     2 taking antibiotics 
     4 severe current dietary restriction 
     12 uncontactable 
     22 declined 
     5 failed to meet severity criteria 
     5 withdrew 7-day baseline phase 
     5 loss to follow up 7-day baseline phase  
  
27 allocated to  
sham diet and placebo   
26 allocated to  
sham diet and probiotic  
24 allocated to 
low FODMAP diet and 
placebo 
27 allocated to  
low FODMAP diet and 
probiotic 
27 included in intention-to-
treat analysis 
26 included in intention-to-
treat analysis 
24 included in intention-to-
treat analysis 
27 included in intention-to-
treat analysis 
22 included in per protocol 
analysis   
5 excluded from analysis  
     1 personal reasons  
     1 protocol violation                 
     1 loss to follow up  
     2 non-compliant with      
     placebo 
22 included in per protocol 
analysis   
4 excluded from analysis  
     2 commenced antibiotics  
     2 non-compliant with      
      probiotic 
25 included in per protocol 
analysis   
2 excluded from analysis 
     1 commenced antibiotic 
     1 non-compliant with  
      probiotic 
18 included in per protocol 
analysis   
6 excluded from analysis 
     3 commenced antibiotics  
     3 non-compliant with  
      placebo 
104 randomised 
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